Halozyme Therapeutics (HALO) BidaskScore is increased to Bought

Halozyme Therapeutics, Inc.

The BidaskScore of Halozyme Therapeutics Inc. HALOHALO shows that the shares of the company are now HALOStrongly Bought Bought by investors.

The BidaskScore of the BiotechnologyBiotechnology shows that the sector is BiotechnologyStrongly Bought Sold since November 22.

Here are the BidAskScore of other related companies in the Biotechnology sector:

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Halozyme Therapeutics, Inc.

Launched in 2016, the BidAskClubBidaskClub allows users to follow the evolution of the US equity market. BidaskClub provides a platform to create portfolios and be informed when a company´s or sector’s BidaskScore changes. BidaskClub is provided by LuxFinAdviceLuxFinAdvice.